Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism

  1. Pablo Laje1,
  2. Lori Halaby2,
  3. N Scott Adzick1,
  4. Charles A Stanley2,*

Article first published online: 25 JUN 2009

DOI: 10.1111/j.1399-5448.2009.00547.x

Issue

Pediatric Diabetes

Pediatric Diabetes

Volume 11, Issue 2, pages 142–147, March 2010

Additional Information

How to Cite

Laje, P., Halaby, L., Adzick, N. S. and Stanley, C. A. (2010), Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatric Diabetes, 11: 142–147. doi: 10.1111/j.1399-5448.2009.00547.x

Author Information

  1. 1

    Department of Surgery, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

  2. 2

    Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

*Charles A Stanley, MD, Department of Pediatrics The Children's Hospital of Philadelphia 34th Street and Civic Center Boulevard Philadelphia PA 19104 USA. Tel: +1 215 590 3421; fax: +1 215 590 1605; e-mail: stanleyc@email.chop.edu

Publication History

  1. Issue published online: 26 FEB 2010
  2. Article first published online: 25 JUN 2009
  3. Submitted 12 march 2009. Accepted for publication 19 May 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (492K)

Keywords:

  • congenital HI;
  • NEC;
  • OTT

Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism.

The somatostatin analog octreotide was used for the first time in the treatment of an infant with congenital hyperinsulinism in 1986. Since then, it is commonly used in the management of congenital hyperinsulinemic hypoglycemias. Despite a wide variety of potential adverse reactions, octreotide is generally well tolerated. It has been extensively demonstrated that octreotide reduces the splanchnic blood flow in a dose-dependent manner, affecting the entire gastrointestinal tract, and some concern has been recently raised regarding the potential implications of this effect in the development of necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. The aim of this report is to present a series of patients treated at our institution in which we observed this association, and review the current related literature.

View Full Article (HTML) Get PDF (492K)